RET-positive Thyroid Cancer: Clinical Trials

1 trial for RET-positive Thyroid Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Terminated 1
Phase 21Terminated 1

Follow RET-positive Thyroid Cancer: new trials by email Literature Review of RET-positive Thyroid Cancer trials Research Report on RET-positive Thyroid Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Alectinib - ALK-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Non-small Cell Lung Cancer (NSCLC)
Phase 1 / Phase 2TerminatedDana-Farber Cancer Institute52017-06-192021-09-27

Narrower conditions

Carcinoma, Non-Small-Cell Lung (1)  ·  Thyroid Neoplasms (1)

Broader conditions

Bronchial Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Head and Neck Neoplasms (1)  ·  Lung Diseases (1)  ·  Lung Neoplasms (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Neoplasms (1)  ·  Thoracic Neoplasms (1)  ·  Thyroid Diseases (1)

Interventions

alectinib (1)

Sponsors

Dana-Farber Cancer Institute (1)

Countries

United States (1)

Top investigators

Mark Awad, MD (1)